Nicox S.A.
https://www.nicox.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nicox S.A.
Roche Adds Ascidian’s RNA-Writing To Its Neurology Push
A first big pharma partnership for Ascidian, headed up by ex-Biogen research head Michael Ehlers, as the Swiss firm expands its gene editing and neuroscience efforts.
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
Why Pheon Is Keeping Mum Over Target For Novel ADC
Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.
Finance Watch: AltruBio, Pheon Raise Venture Capital Mega-Rounds
Private Company Edition: AltruBio raised up to $225m and Pheon garnered $120m in series B financings, while Lycia brought in $106.6m in series C cash. Also, Sands Capital closed its third life science fund, totaling $555m, and NewVale Capital debuted with $167m for life science services.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Topical Delivery
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Laboratoires Doliage
- Eupharmed srl
- Aciex Therapeutics, Inc.
- AVEye Biotechnologie GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice